Related Experiment Video
Updated: May 27, 2025
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Exploring the Therapeutic Potential of Vesicular Nanocarrier Systems for Elimination of Skin Cancer
Lalit Kumar1, Ritesh Rana2, Komal Komal3
1Department of Pharmaceutics, GNA School of Pharmacy, GNA University, Phagwara, Punjab, 144401, India.
Background:
Skin cancer, a common malignancy worldwide, has increased incidence and mortality. Thus, it is a public health issue and a significant illness burden, which increases treatment costs. Chemotherapy and surgery are used to treat skin cancer. However, conventional skin cancer treatments have several limitations, demanding the development of innovative, safe, and effective methods. To overcome these limitations of conventional topical dosage forms, many nanocarriers have been developed and tested for the targeted delivery of anticancer drugs.
Objective:
The main objective of the present review was to discuss the utility of various vesicular nanocarrier systems to deliver anticancer drugs following topical administration to treat skin cancer.
Methods:
For this review article, we scoured the scholarly literature using Science Direct, Google Scholar, and PubMed.
Discussion:
The vesicular drug delivery system has been intensively explored and developed as an alternative to conventional skin cancer drug delivery systems, especially for melanoma. They improve the penetration of anticancer drugs via the skin, reaching the cancer area with enough and killing cancer cells. Vesicles minimize skin irritation and drug degradation. This improves therapy efficacy and reduces systemic toxicity.
Conclusion:
Utilizing the vesicular drug delivery system shows promise in treating skin cancer. Therefore, further research and inquiries are necessary to explore the therapeutic potential of these substances in treating skin cancer, intending to develop a personalized, efficient, and secure therapy approach for patients with this condition.
Insights
Vesicular nanocarriers offer a promising approach for topical skin cancer treatment, enhancing drug delivery and reducing side effects. Further research is needed to optimize these systems for personalized and effective therapies.
Area of Science:
- Dermatology
- Nanotechnology
- Oncology
Background:
- Skin cancer is a prevalent global health concern with rising incidence and mortality.
- Conventional treatments like chemotherapy and surgery have limitations, necessitating novel therapeutic strategies.
- Nanocarriers are being investigated for targeted delivery of anticancer drugs to overcome limitations of traditional topical formulations.
Purpose of the Study:
- To review the application of vesicular nanocarrier systems for topical delivery of anticancer drugs in skin cancer treatment.
Main Methods:
- Literature search conducted across Science Direct, Google Scholar, and PubMed.
Main Results:
- Vesicular drug delivery systems enhance anticancer drug penetration through the skin.
- These systems effectively deliver drugs to target cancer cells, improving efficacy and reducing systemic toxicity.
- Vesicles minimize skin irritation and drug degradation, offering an advantage over conventional methods.
Conclusions:
- Vesicular nanocarriers show significant promise as an alternative to conventional skin cancer treatments, particularly for melanoma.
- Further investigation is crucial to fully realize the therapeutic potential of vesicular systems for personalized, efficient, and safe skin cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Clinical Applications of Epidermal Stem Cells
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy